7752-78-5

Usage

Uses

Used in Pest Control Industry:
5-BROMO-2-METHYL-PYRIMIDINE is used as an insecticide for its strong insecticidal effects on house flies. 5-BROMO-2-METHYL-PYRIMIDINE targets specific biological pathways in insects, leading to their control and management. This application is particularly beneficial in agricultural settings, where house flies can pose a threat to crop health and yield.

InChI:InChI=1/C5H5BrN2/c1-4-7-2-5(6)3-8-4/h2-3H,1H3

Upstream product

• 100707-39-9 5-bromo-2-methyl-pyrimidine-4-carboxylic acid 
• 75-24-1 trimethylaluminum 
• 183438-24-6 5-bromo-2-iodopyrimidine 
• 544-97-8 dimethyl zinc(II) 
• 114078-88-5 5-bromo-1,2,3-triazine 
• 143-37-3 acetamidine 
• 66621-92-9 (5-bromo-pyrimidin-2-yl)-malonic acid diethyl ester 
• 2065-75-0 2-Bromo-malonaldehyde 
• 124-42-5 acetamidine hydrochloride 

Downstream Products

• 1193116-74-3 5-bromo-2-(bromomethyl)pyrimidine 
• 1432731-71-9 methyl 4-(2-fluoro-4-methoxyphenyl)-7-[1-(2-methylpyrimidin-5-yl)propan-2-yl]quinoline-2-carboxylate 
• 1616100-86-7 tert-butyl ((4S,6S)-4-(2,4-difluoro-5-(2-methylpyrimidin-5-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-yl)carbamate 
• 1034924-06-5 (2-methylpyrimidin-5-yl)boronic acid 
• 83410-38-2 ethyl 5-bromo-2-methyl-4-pyrimidinecarboxylate 
• 1609550-57-3 C₁₅H₁₆FIN₄O₃ 
• 1609550-56-2 C₁₅H₁₆FIN₄O₃ 
• 1225223-42-6 1-(2-methylpyrimidin-5-yl)ethanone 
• 1240783-02-1 (5-bromopyrimidin-2-yl)methylamine 

Relevant academic research and scientific papers

Preparation method 2 - methyl -5 -bromopyrimidine

The invention specifically discloses a preparation method of 2 - methyl -5 -bromopyrimidine, and belongs to the technical field of organic synthesis. The method comprises the following steps: a) taking 2 - amino -5 -bromopyrimidine as a raw material, carrying out diazotization reaction or Schedman reaction or 2 - hydroxyl -5 -bromopyrimidine as a raw material to obtain 2 -halo -5 -bromopyrimidine through a halogenated reagent. b) The carboxylic diester is substituted with 2 - halo -5 - bromopyrimidine to give 2-position substituted product. c) The last 2 -bit substituted product is reacted under basic, high temperature conditions to give 2 - methyl -5 - bromopyrimidine. The method has the advantages of easily available raw materials, low cost, simple flow and potential industrial amplification prospect.

Preparation method of 5-bromo-2-substituted pyrimidine compound

The invention discloses a preparation method of a 5-bromo-2-substituted pyrimidine compound. The 5-bromo-2-substituted pyrimidine compound is obtained through a one-step reaction by using 2-bromomalonaldehyde and an amidine compound as raw materials. The

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 al-kyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, halo C1-4 alkyl, CN, C1-C6, alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -SO2C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, ben-zyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z to-gether can be absent

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

Inverse electron demand diels-alder reactions of 1,2,3-triazines: Pronounced substituent effects on reactivity and cycloaddition scope

A systematic study of the inverse electron demand Diels-Alder reactions of 1,2,3-triazines is disclosed, including an examination of the impact of a C5 substituent. Such substituents were found to exhibit a remarkable impact on the cycloaddition reactivity of the 1,2,3-triazine without altering, and perhaps even enhancing, the intrinsic cycloaddition regioselectivity. The study revealed not only that the reactivity may be predictably modulated by a C5 substituent (R = CO2Me > Ph > H) but also that the impact is of a magnitude to convert 1,2,3-triazine (1) and its modest cycloaddition scope into a heterocyclic azadiene system with a reaction scope that portends extensive synthetic utility, expanding the range of participating dienophiles. Significantly, the studies define a now powerful additional heterocyclic azadiene, complementary to the isomeric 1,2,4-triazines and 1,3,5-triazines, capable of dependable participation in inverse electron demand Diels-Alder reactions, extending the number of complementary heterocyclic ring systems accessible with implementation of the methodology.